Dimension Inx Raises $12M Series A to Accelerate Commercialization of New Generation of Regenerative Therapeutics

In addition to its Series A funding, Dimension Inx receives U.S. FDA 510(k) for CMFlextm, the first 3D-printed regenerative product cleared by the FDA

CHICAGO, Feb. 1, 2023 /PRNewswire-PRWeb/ -- Dimension Inx, a biomaterials platform company, announced today that they have closed a $12M Series A Round. The round was led by Prime Movers Lab (PML), with participation by returning investors KdT Ventures and Revolution's Rise of the Rest Seed Fund (ROTR). New investors participating in the round include Solas BioVentures, Portal Innovation Ventures, and Alumni Ventures.

Dimension Inx is a biomaterials platform that designs, develops, and manufactures therapeutic products. Enabling a new generation of regenerative therapeutics, Dimension Inx's platform engineers three-dimensional microenvironments that direct cell behavior and allow the body to restore tissue and organ function more effectively.

The Chicago-based company will use the funding to advance the development of their therapeutics focused on functional organ restoration, and expand their manufacturing capabilities. In the near term, the company will use the funds to support the commercial launch of their first product, CMFlextm.

"We pride ourselves in catalyzing a step function change to unlock the full potential of regenerative therapeutics to cure complex disease, and we're grateful to do so with the support of our investors," stated CEO of Dimension Inx, Caralynn Nowinski Collens, M.D. "Our approach has always focused on the entire tissue microenvironment. If we provide the right blueprint, we make it possible to recruit the body's natural strengths and accelerate the repair, regeneration, and ultimately, restoration of critical body function."

"Dimension Inx represents the type of breakthrough science we believe will transform their industry and reshape our physical world," said Prime Movers Lab Venture Partner Amy Kruse, Ph.D. who will be joining the company's board. "We're excited to support Dimension Inx as they enter this next phase of growth and development, and bring their transformative products to market."

In addition to their Series A funding, Dimension Inx also announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance for CMFlextm, the first 3D-printed regenerative bone graft product cleared by the FDA. As a ready-to-use flexible ceramic for oral and maxillo-facial indications, CMFlex improves clinician workflow and reduces surgical case time for clinicians, while restoring healthy bone.

"FDA clearance is a major milestone for our platform, and validates the work we've put into developing our product over the past two years," said Dr. Collens. "CMFlex is a product that represents our unique approach to restoring functionality in the body: it's a dynamic collaboration between biology, material composition, microstructure, and macroarchitecture. We're excited by the interest we've already received from surgeons who recognize the importance of a ready-to-use solution that is easy to handle and accelerates healing to improve patient outcomes."

To learn more about Dimension Inx and its platform, click here: http://www.dimensioninx.com.

ABOUT DIMENSION INX

Dimension Inx is a biomaterials platform company. We design and develop therapeutic products that restore tissue and organ function.

Our materials-centric approach enables biofunctionality without compromising manufacturability. We precisely tune our biomaterials to create clinical solutions not otherwise possible. We work shoulder-to-shoulder with biotech and medical device partners to help solve their most challenging materials problems, and internally develop medical products for various therapeutic applications ranging from bone regeneration to fertility preservation.

Dimension Inx is proudly based in Chicago, IL. To learn more about our team and our technology, please visit http://www.dimensioninx.com.

Dimension Inx. Biomaterials, reimagined.

ABOUT PRIME MOVERS LAB

Prime Movers Lab invests in breakthrough scientific startups founded by Prime Movers, the inventors who transform billions of lives. We invest in companies reinventing energy, transportation, infrastructure, manufacturing, agriculture and human augmentation. Portfolio investments span in-space transportation, industrial solar heat, ag tech, brain upgrades, nano-structured materials, wafer slicing, prosthetics, 3D printing, mobility, longevity and AI.

Media Contact

Alexa Ball, Jones-Dilworth Inc., 217-953-1638, [email protected]

SOURCE Dimension Inx